SCHEMBL661941

SCHEMBL661941

Cc1noc(C2CCNC2)n1

nearest known ligand 0.52

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.41
MPO P05164 1/20 0.39
NR1H4 Q96RI1 1/20 0.38
PLAT P00750 2/20 0.38
TLR9 Q9NR96 2/20 0.38
TLR8 Q9NR97 2/20 0.38
TLR7 Q9NYK1 2/20 0.38
OGA O60502 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL661940 1.00 CHRM2 (0.41) CHRM2MPONR1H4PLATTLR9
SCHEMBL662801 1.00 CHRM2 (0.41) CHRM2MPONR1H4PLATTLR9
Hydrochloric Acid SCHEMBL3693872 0.98 CHRM2 (0.40) CHRM2MPONR1H4PLATTLR9
SCHEMBL661261 0.90 KDM1A (0.41) CHRM2TLR9TLR8TLR7
SCHEMBL660436 0.90 KDM1A (0.41) CHRM2TLR9TLR8TLR7
SCHEMBL661670 0.90 KDM1A (0.41) CHRM2TLR9TLR8TLR7
SCHEMBL979120 0.89 NR1H4 (0.47) CHRM2NR1H4PLATOGA
SCHEMBL661604 0.88 MPO (0.37) CHRM2MPONR1H4PLATTLR9
SCHEMBL661436 0.88 MPO (0.37) CHRM2MPONR1H4PLATTLR9
SCHEMBL662417 0.88 MPO (0.37) CHRM2MPONR1H4PLATTLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853219-B2 Compounds and compositions for cognition-enhancement, methods of making, and methods of treating NEUROSOLIS, INC. (US) 2014-10-07 US claimed
EP-2523944-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING Mithridion, Inc. (US) 2012-11-21 EP claimed
US-20120046273-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2012-02-23 US claimed
EP-2403340-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING Mithridion, Inc. (US) 2012-01-11 EP claimed
US-20110263613-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MAPLIGHT THERAPEUTICS, INC. 2011-10-27 US claimed
WO-2011085406-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2011-07-14 WO claimed
WO-2010102218-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2010-09-10 WO claimed
EP-3573987-B1 TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARM SPA (IT) 2021-03-10 EP disclosed
US-20180099956-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MITHRIDION, INC. 2018-04-12 US disclosed
US-20180099956-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MITHRIDION, INC. 2018-04-12 US disclosed
US-20180099956-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating MITHRIDION, INC. 2018-04-12 US disclosed
US-20170313687-A1 Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating NEUROSOLIS INC (US) 2017-11-02 US disclosed
US-20170313687-A1 Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating NEUROSOLIS INC (US) 2017-11-02 US disclosed
WO-2010102218-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2010-09-10 WO disclosed
WO-2010077992-A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-07-08 WO disclosed
US-20100160280-A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-06-24 US disclosed
US-20100160280-A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-06-24 US disclosed
US-20100137278-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-06-03 US disclosed
US-20100137278-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-06-03 US disclosed
WO-2010057121-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137278-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS PDE10A, PDE12, PDE5A CHRM2 3706/4885MPO 315/4885NR1H4 3771/4885
US-20120046273-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING CHRM3, CHRM4, CHRM5 CHRM2 4/4885MPO 1878/4885NR1H4 236/4885
US-20110263613-A1 COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING CHRM3, ACHE, CHRM4 CHRM2 6/4885MPO 1068/4885NR1H4 498/4885
US-20180099956-A1 Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating CHRM3, CHRM4, CHRM5 CHRM2 4/4885MPO 2290/4885NR1H4 586/4885
US-20170313687-A1 Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating CHRM3, ACHE, CHRM4 CHRM2 6/4885MPO 1068/4885NR1H4 498/4885
US-20100160280-A1 AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS PDE4A, PDE7A, PDE4D CHRM2 109/4885MPO 330/4885NR1H4 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.